Dr. Reddy's Laboratories RDY announced today that is has
launched Lamotrigine Extended-Release Tablets (25 mg, 50 mg, 100 mg, 200
mg, 300 mg) a therapeutic equivalent generic version of Lamictal®
XR (lamotrigine) in the US market on June 25, 2013, following the
approval by the United States Food & Drug Administration (USFDA) of Dr.
Reddy's ANDA for Lamotrigine XR tablets.
The Lamictal® XR brand and generic had combined U.S. sales of
approximately $300.5 Million MAT for the most recent twelve months
ending in April 2013 according to IMS Health*.
Dr. Reddy's Lamotrigine XR Tablets 25 mg, 50 mg, 100 mg, 200 mg, and 300
mg are available as unit of use bottles of
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in